Institutional investors purchased a net $278.7 thousand shares of CYCC during the quarter ended September 2017. This may signal that the smart money is gaining interest in this company as the 24.79% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THE VANGUARD GROUP, INC. Bought 89.0 Thousand shares of Cyclacel Pharmaceuticals ...